NCT06972459 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06967610 Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Status RECRUITING Phase PHASE2
NCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06952530 A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 Status RECRUITING Phase PHASE3
NCT06948786 Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial Status RECRUITING Phase PHASE2
NCT06948435 A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Status RECRUITING Phase PHASE3
NCT06948422 A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) Status RECRUITING Phase PHASE3
NCT06945419 A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes Status RECRUITING Phase PHASE1
NCT06945406 A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes Status RECRUITING Phase PHASE1
NCT06937411 A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants Status COMPLETED Phase PHASE1
NCT06937099 Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight Status RECRUITING Phase PHASE3
NCT06937086 Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Status RECRUITING Phase PHASE3
NCT06921759 A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06916143 Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06916091 A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight Status COMPLETED Phase PHASE1
NCT06916078 A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function Status RECRUITING Phase PHASE1
NCT06916065 A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity Status COMPLETED Phase PHASE1
NCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06911944 Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation Status NOT_YET_RECRUITING Phase PHASE4